Skip to search boxSkip to navigationSkip to main content

Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients

  • Adviye Ergul
    ,
  • Vera Portik-Dobos
    ,
  • Jimmie Hutchinson
    ,
  • Jennifer Franco
    ,
  • Mark P. Anstadt
  • University of Georgia
    ,
  • Medical College of Georgia
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Peripheral vasculature undergoes extensive vascular remodeling in the hypertensive state. Regulation of extracellular matrix turnover by the matrix metalloproteinase (MMP) system is an important step in the vascular remodeling process. However, the expression pattern of the vascular MMP system in human hypertension remained unknown. Internal mammary artery specimens were obtained from normotensive (n = 13) and hypertensive (n = 19) patients undergoing coronary artery bypass grafting surgery. Zymographic analysis indicated a threefold decrease in total gelatinolytic activity of MMP-2 and MMP-9 in hypertension. MMP-1 activity was also decreased by fourfold without a significant change in protein levels. Tissue levels of extracellular matrix inducer protein (EMMPRIN), MMP activator protein (MT1-MMP), MMP-1, MMP-2, and MMP-9, as well as tissue inhibitors of MMPs (TIMP-1 and TIMP-2) were assessed by immunoblotting and yielded a significant decrease in MMP-9, EMMPRIN, and MT1-MMP levels in hypertension. In addition, measurement of plasma markers of collagen synthesis (procollagen type I amino-terminal propeptide [PINP]) and collagen degradation (carboxy-terminal telopeptide of collagen type I [ICTP]) indicated no difference in PINP levels but suppressed degradation of collagen in hypertension. Evaluation of profibrotic growth factors demonstrated higher levels of fibroblast growth factor (FGF)-2 in tissue preparations from hypertensive patients but no difference in transforming growth factor-β1 levels. These findings demonstrate that not only MMP-1 and MMP-9, but MMP inducer and activator proteins are also downregulated in the hypertensive state. Augmented FGF-2 levels may contribute to parallel decreases in MMP activity and MMP induction system resulting in enhanced collagen deposition in hypertension.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 775-782 (8 pages)

Journal (Volume, Issue Number)

American journal of hypertension (Volume 17, Issue 9)

Publication milestones

  • Published - 09/2004

Publication status

Published - 09/2004

ISSN

0895-7061

Publication IDs

  • Scopus: 4444325595
  • PubMed: 15363819

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
SciVal
citations
40
SciVal
FWCI
0.71
SciVal
Author count
5
SciVal
Paper percentile
82

PlumX, opens in new tab

Citation count
44
Captures
22

Funding Details

Dr. Ergul is the recipient of the American Heart Association Scientist Development Grant, American Diabetes Association Research Award, and Pfizer Atorvastatin Research Award.